Other

Nanopharmaceuticals LLC

Shifa Biomedical Corporation

The Dupont Merck Pharmaceutical Company

Biovec Transfusion, LLC

Vascular Vision Pharmaceutical Company

Temple University

Bristol-myers Squibb Pharma Company

Polymedix, Inc.

Virothera Pharmaceuticals LLC

Dupont Pharmaceuticals Company

Ordway Research Institute, Inc.

Avant Garde Therapeutics and Technologies LLC

E.i. Dupont De Nemours and Company

Dupont Pharmaceuticals, Inc.

Shaker Ahmed Mousa

Paul J Davis

Faith B Davis

Nabil A Elshourbagy

William Frank Degrado

Harold V Meyers

Sherin Salaheldin Abdel-Meguid

Mehdi Rajabi

John Wityak

Lakshman R Sehgal

Ozlem O Karakus

Robert J Linhardt

Bruce Allan Hay

Dahui Liu

Michael Sworin

Robert W Colman

Mohammed H Qari

Anju Parthasarathy

Sharon Anne Jackson

Richard Eric Olson

Shuang Liu

Chu-Biao Xue

Douglas G Batt

Milind Rajopadhye

Thomas David Harris

Donald J Pinto

Gary Avonn Cain

Leo Rubin

Munir A Hussain

Gregory J Wells

Mawaheb M El-Naggar

Thais Motria Sielecki-Dzurdz

Mohammed S Ardawi

John Andrew Barrett

Scott David Edwards

Magid A Abou-Gharbia

Mark Andrew Scialdone

Wayne Everett Childers

Benjamin E Blass

Steven Willis Shuey

William F DeGrado

Pancras C Wong

Rogelio Martinez

Hung-Yun Lin

Deena Shaker Mousa

Gennadi V Glinksy

Ali Hafez Ali Mohammed ElFar

Victor Ghidu

Aleck Hercbergs

Gennadi V Glinsky

Sarah Mousa

Mohammed-Salleh M Ardawi

Abdulqader Al Haider

Abdelgalil Abdelgader

Abdullah M Aldahmash

Abdulkareem Almomen

Amna Saddiq

Maria Rafalski

Maria Alexander-Bridges

Disclosed are Nanoformulated compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL- and related cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) nano-formulation of compounds and methods of using the same

A method for prevention or treatment of a viral-mediated infectious disease in a mammal. The mammal may be a human being. A therapeutic dose of a composition is administered, via an inhalation delivery apparatus, to the mammal. The composition includes microparticles and/or nanoparticles. The microparticles and/or nanoparticles include a first pharmaceutically active agent and a second pharmaceutically active agent. The first pharmaceutically active agent includes unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), sulfated non-anticoagulant heparin (S-NACH) or combinations thereof. The second pharmaceutically active agent includes 10-30 mg of hydroxychloroquine in a form of hydroxychloroquine sulfate, 10-30 mg of favipiravir, or a combination thereof. The viral-mediated infectious disease is caused by one or more viruses in the mammal.

Method for treatment of a viral-mediated infectious disease

Chemical compounds/compositions, methods of synthesis, and methods of use are provided. The compounds/compositions are directed toward thyrointegrin antagonists directly conjugated to a polymer. The compounds/compositions may further comprise an additional substituent also conjugated to the polymer. The compounds/compositions may demonstrate antiangiogenic effect and efficacy against conditions, particularly cancers.

Polymer conjugated thyrointegrin antagonists

Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward thyroid hormone &#x3b1;v&#x3b2;3 integrin receptor antagonists conjugated to targets of the norepinephrine transporter (NET) or the catecholamine transporter. The compositions have a dual targeting effect and increased targeting efficiency in the treatment and diagnostic imaging of neuroendocrine tumors.

Composition and method for dual targeting in treatment of neuroendocrine tumors

Chemical compounds/compositions, methods of synthesis, and methods of use. The compounds/compositions are directed toward thyrointegrin antagonists conjugated to a polymer. The compounds/compositions further comprise an additional substituent also conjugated to the polymer. The compounds/compositions demonstrate increased uptake across the blood brain barrier along with increased retention therein and retention within tumor. The compounds/compositions may also include improved synthesis scalability, improved purity, improved aqueous solubility, and a solid product or intermediate. The compounds/compositions may demonstrate improved antiangiogenic effect and improved efficacy against conditions, particularly cancers, requiring blood brain barrier permeability, for example, glioblastoma (GBM).

Composition of scalable thyrointegrin antagonists with improved retention in tumors

An environmentally natural protective and therapeutic (ENPT) mask and an associated method of forming the ENPT mask. The ENPT mask includes: a face mask; and one or more essential oils embedded in the face mask. The one or more essential oils are configured to destroy microbes in direct physical contact with the one or more essential oils. The method of forming the ENPT mask includes embedding the one or more essential oils in the face mask.

Environmentally natural protective and therapeutic (ENPT) face mask

A composition and method for treating a mammal infected with a virus therein, and an inhalation delivery system for prevention and treatment of upper respiratory tract viruses, by administering a therapeutic dose of the composition to the mammal. The composition includes:

Method and composition for treating upper respiratory tract inflammatory and infectious diseases

Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors

Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases

Chemical compositions and methods of synthesis thereof. The compositions disclosed and described herein are directed toward and classified as anti-angiogenic thyrointegrin antagonists, which may be capable of reacting with one or more cell surface receptors of the integrin &#x3b1;v&#x3b2;3 receptor family. Anti-angiogenic thyrointegrin antagonists or derivatives thereof are conjugated via a non-cleavable linker having an amine, diamine or triazole linkage to polymers of Polyethylene Glycol, cyclodextrin, chitosan, alginic acid or hyaluronic acid, forming a single chemical entity. Utility of the compositions disclosed may treat angiogenesis-mediated disorders such as Cancer (Solid tumors and Liquid tumors), ocular disorders (Diabetic Retinopathy and Age-related Macular Degeneration), inflammatory disorders (arthritis, osteoarthritis), atherosclerosis, lesions, and dermatology (Rosacea, Psoriasis, skin cancer) and diseases mediated or dependent upon the generation of new blood cells via angiogenesis to persist and the treatment thereof or dependent on antagonizing the formation of new blood vessels to slow or eliminate angiogenic pathways.

Non-cleavable polymer conjugated with alpha V beta 3 integrin thyroid antagonists

Endothelial Lipase (EL) inhibitors and methods of using such inhibitors for treating conditions implicating EL are provided herein. The present invention meets the needs in the field by providing small molecule inhibitors of EL function that can be used therapeutically to raise HDL cholesterol levels in blood, and can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including, but not limited to, familial hypercholesterolemia, atherogenic dyslipidemia, atherosclerosis, and, more generally, cardiovascular disease (CVD).

Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases

Non-cleavable polymer conjugated with &#x3b1;V&#x3b2;3 integrin thyroid antagonists

Growing community of inventors

Rensselaer, NY, United States of America

Shaker Ahmed Mousa